Very activeNews release:
"Further, over the past quarter we remained very active with our activities related to strategic corporate initiatives."
"- Ongoing strategic corporate discussions progressing and continued planning for uplisting to Nasdaq"
Sounds very active but is CZO best positioned at this moment?
It seems like the best path would be to complete the 50L and 100L scale-up, complete the Phase I/II a avenanthramide clinical trial establising a safety profile and preliminary efficacy, complete the preclinical toxicology study for the fibrosis drug and make a Phase I clinical decision, complete the scale-up of the malting technology and on the strength of a licensing deal for PGX-CoQ10 do a simultaneous listing on NASDAQ. CZO's base business will have had a chance to demonstrate its return to normalcy. In the nearer term there could be a deal for a new revenue generating asset.
How will it unfold to maximize shareholder value. These type of situations can produce windfalls gains and immediate punishment if not done right.